Replies to post #207398 on Biotech Values

[DewDiligence]

OCRX—I agree with Dew about the Ravicti [data] not exactly…de-risking [OCRX’s STOP-HE trial] since it was a completely different trial.

I would elaborate on the above by noting that the Ravicti trial was in secondary prevention of HE, while STOP-HE is in acute treatment of HE, a rather different indication. Moreover, the time-to-event (secondary) endpoint in the Ravicti trial bears no relationship to the time-to-event primary endpoint in STOP-HE; the former measures time to emergence of HE, while the latter measures time to meaningful recovery from HE.

Bottom line: The Wainwright analyst is simply regurgitating OCRX’s talking points by saying that the Ravicti data substantially de-risk STOP-HE.